XORTX Therapeutics Inc.
TSXV XRTX.V
XORTX Therapeutics Inc. Shareholders' Equity for the year ending December 31, 2023: USD 4.64 M
-
XORTX Therapeutics Inc. Shareholders' Equity for the year ending December 31, 2022 was USD 5.15 M, a -50.42% change year over year.
-
XORTX Therapeutics Inc. Shareholders' Equity for the year ending December 31, 2021 was USD 10.38 M.
| Date | Shareholders' Equity | Minority Interest | Total Equity | Total Stockholders Equity and Liabilities |
|---|
Don’t Miss A Beat
| CEO | Dr. Allen Warren Davidoff Ph.D. |
| IPO Date | Nov. 5, 2021 |
| Location | Canada |
| Headquarters | 421 – 7th Avenue SW |
| Employees | 2 |
| Sector | Healthcare |
| Industries | |
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Past 5 years
USD 5.90
StockViz Staff
February 6, 2025
Any question? Send us an email